PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展

doi:10.12092/j.issn.1009-2501.2018.08.018

摘要/Abstract

摘要：

程序性死亡受体1（programmed death-1，PD-1）是T细胞表面一类重要的共抑制分子，对免疫反应起负性调节作用。PD-1与其配体程序性死亡受体配体1（programmed death ligand 1，PD-L1）结合可抑制肿瘤组织周围的免疫微环境，导致特异性T细胞活性下调，促使肿瘤细胞逃避免疫监视。PD-1/PD-L1抑制剂可以阻断这一信号通路，并激活抗肿瘤免疫应答，抑制肿瘤细胞的生长。本文就PD-1/PD-L1 通路抑制剂在不同消化道肿瘤免疫治疗中的研究进展作一综述。

关键词: PD-1/PD-L1, 通路抑制剂, 消化系统肿瘤, 免疫治疗

Abstract:

Programmed cell death-1(PD-1) is an important co-inhibitory molecule expressing on T cell that has negative regulations on immune responses. When PD-1 bound to its ligand programmed cell death-ligand (PD-L1), PD-1/PD-L1 pathway can restrain the immune microenvironment, leading to the down-regulation of tumor-specific T cell activity, and contribute to tumor cells avoiding the immune surveillance and immune escape. PD-1/PD-L1 inhibitors may block its signaling pathway and enhance immune responses, thus inhibiting the growth of tumor cells. In this review, we discuss the therapeutics use of PD-1/PD-L1 monoclonal blocking antibodies in the immunotherapy of digestive system neoplasm.

Key words: PD-1/PD-L1, pathway inhibitors, neoplasms of digestive system, immunity therapy

中图分类号:

R735

蒙秋华，田婧，覃斐章，覃杨，董敏. PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8): 942-948.

MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min. Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 942-948.

参考文献

［1］Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132.
［2］Saito T, Yokosuka T, Hashimoto-Tane A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters［J］. FEBS Lett, 2010, 584(24):4865-4871.
［3］Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion ［J］. Science, 2011, 331(6024):1565-1570.
［4］Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy ［J］. J Drug Target, 2018, 20:1-13.
［5］Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy［J］. J Hematol Oncol, 2017, 10(1):174.
［6］Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death ［J］. EMBO J, 1992, 11(11): 3887-3895.
［7］Sidorenko SP , Clark EA. The dual-function CD150 receptor subfamily: the viral attraction［J］. Nat Immunol, 2003, 4(1):19-24.
［8］Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity［J］.Clin Immunol , 2014, 153(1):145-152.
［9］Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal［J］. Nat Immunol, 2009, 10(11):1185-1192.
［10］Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases［J］. Cell Immunol, 2014, 290(1):72-79.
［11］Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer［J］. J Clin Oncol, 2015, 33(18):2004-2012.
［12］Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancer, 2017, 390(10111):2461-2471.
［13］El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial［J］. Lancet, 2017, 389(10088):2492-2502.
［14］Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study［J］. Lancet Oncol, 2017, 18(9):1182-1191.
［15］Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma［J］. N Engl J Med, 2018, 378(14):1277-1290.
［16］Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden ［J］. N Engl J Med, 2018, 378(22):2093-2104.
［17］Grimm MO, Oppel-Heuchel H, Foller S , et al. Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects［J］. Urologe A, 2018, 57(5):543-551.
［18］Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial［J］. Lancet Oncol, 2016, 17(6):717-726.
［19］Falchi L, Sawas A, Deng C, et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory hodgkin lymphoma previously exposed to epigenetic therapy［J］. J Hematol Oncol, 2016, 9(1):132.
［20］Saito H, Kono Y, Murakami Y, et al. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression ［J］. Anticancer Res, 2018, 38(1):107-112.
［21］Jung HI, Jeong D, Ji S, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma［J］. Cancer Res Treat, 2017, 49(1):246-254.
［22］Yagi T, Baba Y, Ishimoto T, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer ［J］. Ann Surg, 2017, dol:10.1097/SLA.0000000000002616.
［23］Valentini AM, Di Pinto F, Cariola F, et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments［J］. Oncotarget, 2018, 9(9):8584-8596.
［24］Torre LA, Bray F, Sieqel RL, et al. Global cancer statistics,2012［J］.CA Cancer J Clin, 2015, 65(2):87-108.
［25］Long J, Lin J, Wang A, et al. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy［J］. J Hematol Oncol, 2017, 10(1):146.
［26］Mazzolini GD, Malvicini M. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. trends and perspectives［J］. Medicina (B Aires), 2018, 78(1):29-32.
［27］Yunching Chen, Ramjiawan RR, Thomas Reiberger, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice［J］. Hepatology, 2015, 61(5):1591-1602.
［28］Moris D, Rahnemai-Azar AA, Zhang X, et al. Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors［J］. Surg Oncol, 2017, 26(4):423-430.
［29］Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma［J］. Lancet, 2013, 381(9864):400-412.
［30］Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes［J］. Nature, 2013, 499(7457):214-218.
［31］Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］.Science, 2015, 348(6230):124-128.
［32］Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer［J］. Clin Cancer Res, 2005, 11(8):2947-2953.
［33］Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma［J］. J Clin Oncol, 2018, 36(1):61-67.
［34］Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial［J］. Lancet Oncol, 2017, 18(5):631-639.
［35］Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon［J］. Science, 1993, 260(5109):816-819.
［36］Diaz LA, Le DT. PD-1 blockade in tumors with mismatch-repair deficiency［J］. N Engl J Med, 2015, 373(20):1979.
［37］Lin AY, Lin E. Programmed death 1 blockade, an achilles heel for MMR-deficient tumors［J］. J Hematol Oncol, 2015, 8:124.
［38］Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer［J］.Lancet, 2016,388(10039):73-85.
［39］Feng M, Xiong G, Cao Z , et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer［J］. Cancer Lett, 2017, 407:57-65.
［40］Soares KC, Rucki AA, Wu AA, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors［J］. J Immunother, 2015, 38(1): 1-11.
［41］Zhou NX, Huang ZQ, Zhang WZ, et al. The comprehensive analysis of the clinical classification，surgical methods and long term effects of 402 cases of hilar cholangiocarcinoma［J］. Chin J Surg, 2006, 44(23):1599 -1603.
［42］刘谋泽, 李浩, 张伟. 肝内胆管癌病理机制表观基因组学研究进展［J］.中国临床药理学与治疗学, 2014, 19(11):1294-1298.
［43］Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma［J］. Ann Surg Oncol, 2016, 23(8):2610-2617.
［44］Ye Y, Zhou L, Xie X, et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion［J］. J Surg Oncol, 2009, 100(6):500-504.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[4]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[5]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[6]	赵全铭，杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[7]	刘红丹，殷一红. 麒麟丸预防体外受精胚胎移植术后所致卵巢过度刺激综合征患者的疗效及对血浆相关指标的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 196-202.
[8]	毛曦轲, 喻辰晞, 黄滔, 毛桐俊, 吴志浩. 内质网应激及其在肺癌中作用的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(10): 1160-1170.
[9]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[10]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[11]	章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.
[12]	王韦力，廖萍，许标波，周成芳，谢商宸，沈冬亚，贺毅憬，Howard L. Mcleod. 肿瘤免疫检查点抑制剂个体化用药策略研究进展[J]. 中国临床药理学与治疗学, 2017, 22(2): 228-232.
[13]	杨何，张升，辛艳飞. 肿瘤免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2016, 21(9): 1074-1080.
[14]	艾雄飞，杜丹玉，孙立，林森森，袁胜涛. 靶向肿瘤相关巨噬细胞的治疗进展及风险[J]. 中国临床药理学与治疗学, 2016, 21(6): 697-702.
[15]	许标波，贺毅憬，王韦力，周成芳，谢商宸，沈冬亚，Howard L. Mcleod. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224.